MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
12 oct. 2022 08h00 HE
|
MaxCyte, Inc
ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
28 sept. 2022 08h05 HE
|
MaxCyte, Inc
Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™ for...
MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor
21 sept. 2022 08h05 HE
|
MaxCyte, Inc
Expanded facilities illustrate MaxCyte’s commitment to Montgomery County and the state of Maryland, building the life sciences community, and propelling local job opportunities. ROCKVILLE, Md., Sept....
MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
07 sept. 2022 16h05 HE
|
MaxCyte, Inc
ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results
10 août 2022 16h05 HE
|
MaxCyte, Inc
45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- MaxCyte,...
MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022
15 juil. 2022 08h00 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs
12 juil. 2022 08h00 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., July 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 mai 2022 16h30 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte Reports First Quarter Financial Results
09 mai 2022 16h05 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., May 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
MaxCyte to Participate in Upcoming Investor Conferences
03 mai 2022 16h05 HE
|
MaxCyte, Inc
GAITHERSBURG, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...